GRI Bio closed at $1.43 on Nov 4, down 7.14%, 97.6% below its 52-week closing high. Volume of 48.6K shares was 1.18× its 20-day average (close to normal).
Split-adjusted performance: -24.7% over one month, -39.4% over six months, -96.8% over one year.
Short interest was 66.1K shares at the Oct 15 settlement, down 4.8% from the prior report (3.0% of float, 1.6 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| GRIGRI Bio | $1.43 | −7.14% | −39.4% | — | — | — | $3.1M | |
| MBIOMustang Bio | $0.4138 | +1.07% | −44.6% | — | — | — | $3.1M | Compare |
| JUNSJupiter Neurosciences | $2.46 | +1.23% | −91.0% | — | −9380.9% | — | $3.2M | Compare |
| SILOSilo Pharma | $1.33 | +3.91% | −78.9% | −100.0% | — | — | $2.9M | Compare |
| SXTP60 Degrees Pharmaceuticals | $0.9563 | −5.32% | −42.4% | −32.5% | −1152.6% | — | $3.4M | Compare |
| KALAKALA BIO | $0.1781 | +2.95% | −96.9% | — | — | — | $3.4M | Compare |
| MDCXMedicus Pharma | $1.88 | −7.39% | −88.7% | — | — | — | $3.6M | Compare |
| CVKDCadrenal Therapeutics | $1.06 | −6.19% | −82.8% | — | — | — | $3.8M | Compare |
| ONCOOnconetix | $0.6583 | +15.69% | −85.4% | −83.9% | −16748.3% | — | $3.9M | Compare |
No recent articles focused on GRI Bio.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
